Elevated serum complement factors 3 and 4 are strong inflammatory markers of the metabolic syndrome development: A longitudinal cohort study

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Liu, Zhenfang ^a,b,c   Tang, Qin ^a   Wen, Jing ^a   Tang, Yan ^a   Huang, Damin ^a   Huang, Yuzhen ^a   Xie, Jinling ^a   Luo, Yawen ^a   Liang, Min ^a   Wu, Chunlei ^a,d   Lu, Zheng ^a,e   Tan, Aihua ^a   Gao, Yong ^a   Wang, Qiuyan ^a,b,c   Jiang, Yonghua ^a,b,c   Yao, Ziting ^a,b,c   Lin, Xinggu ^a,b,c   Zhang, Haiying ^a   Mo, Zengnan ^a,b,c,e   Yang, Xiaobo ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b Guangxi Key Laboratory of Genomic and Personalized Medicine   (China)

^c Center for Genomic and Personalized Medicine   (China)

^d XINXIANG MEDICAL UNIVERSITY   (China)

^e FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4;

ADOLESCENT; ADULT; AGED; BLOOD; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; COHORT STUDIES; COMPLEMENT C3; COMPLEMENT C4; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; INFLAMMATION MEDIATORS; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; RISK FACTORS; YOUNG ADULT;

EID: 84952941289     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18713     Document Type: Article

References (46)

1. International diabetes federation, the IDF consensus worldwide definition of the metabolic syndrome. (2006) Available at: http://www. idf.org/metabolic-syndrome. (accessed: 3rd April 2007)
2. Eckel, R. H., Alberti, K. G., Grundy, S. M. & Zimmet, P. Z. The metabolic syndrome. Lancet. 375, 181-183 (2010).
3. Stern, M. P. et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes care. 27, 2676-2681 (2004).
4. Ishino, K., Mutoh, M., Totsuka, Y. & Nakagama, H. Metabolic syndrome: A novel high-risk state for colorectal cancer. Cancer lett. 334, 56-61 (2013).
5. McNeill, A. M. et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes care. 28, 385-390 (2005).
6. Hotamisligil, G. S. Inflammation and metabolic disorders. Nature. 444, 860-867 (2006).
7. Kovanen, P. T., Manttari, M., Palosuo, T., Manninen, V. & Aho, K. Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. Arch. Intern. Med. 158, 1434-1439 (1998).
8. Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Engl. J. Med. 342, 836-843 (2000).
9. Sesso, H. D., Wang, L., Buring, J. E., Ridker, P. M. & Gaziano, J. M. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension 49, 304-310 (2007).
10. Sesso, H. D. et al. C-reactive protein and the risk of developing hypertension. Jama. 290, 2945-2951 (2003).
11. Bertoni, A. G. et al. Inflammation and the incidence of type 2 diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes care. 33, 804-810 (2010).
12. Bruno, G. et al. C-reactive protein and 5-year survival in type 2 diabetes: The Casale Monferrato Study. Diabetes. 58, 926-933 (2009).
13. Duncan, B. B. et al. Low-grade systemic inflammation and the development of type 2 diabetes: The atherosclerosis risk in communities study. Diabetes. 52, 1799-1805 (2003).
14. Nilsson, J., Jovinge, S., Niemann, A., Reneland, R. & Lithell, H. Relation between plasma tumor necrosis factor-Alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 18, 1199-1202 (1998).
15. Jenny, N. S. et al. Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 209, 226-229 (2010).
16. Xu, H. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821-1830 (2003).
17. Dandona, P., Aljada, A. & Bandyopadhyay, A. Inflammation: The link between insulin resistance, obesity and diabetes. Trends. Immunol. 25, 4-7 (2004).
18. Hotamisligil, G. S., Shargill, N. S. & Spiegelman, B. M. Adipose expression of tumor necrosis factor-Alpha: direct role in obesity-linked insulin resistance. Science. 259, 87-91 (1993).
19. Aso, Y. et al. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombinactivatable fibrinolysis inhibitor. Diabetes care. 28, 2211-2216 (2005).
20. Zarkadis, I. K., Mastellos, D. & Lambris, J. D. Phylogenetic aspects of the complement system. Dev. Comp. Immunol. 25, 745-762 (2001).
21. Puchau, B., Zulet, M. A., Gonzalez de Echavarri, A., Navarro-Blasco, I. & Martinez, J. A. Selenium intake reduces serum C3, an early marker of metabolic syndrome manifestations, in healthy young adults. Eur. J. Clin. Nutr. 63, 858-864 (2009).
22. Phillips, C. M. et al. Complement component 3 polymorphisms interact with polyunsaturated fatty acids to modulate risk of metabolic syndrome. Am. J. Clin. Nutr. 90, 1665-1673 (2009).
23. Onat, A., Hergenc, G., Can, G., Kaya, Z. & Yuksel, H. Serum complement C3: A determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-Aged population. Metabolism. 59, 628-634 (2010).
24. Grant, R. W. & Dixit, V. D. Adipose tissue as an immunological organ. Obesity (Silver Spring) 23, 512-518 (2015).
25. Gregor, M. F. & Hotamisligil, G. S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29, 415-445 (2011).
26. van Oostrom, A. J., Alipour, A., Plokker, T. W., Sniderman, A. D. & Cabezas, M. C. The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. Atherosclerosis 190, 167-173 (2007).
27. Gabrielsson, B. G. et al. High expression of complement components in omental adipose tissue in obese men. Obes. Res. 11, 699-708 (2003).
28. Engstrom, G., Hedblad, B., Eriksson, K. F., Janzon, L. & Lindgarde, F. Complement C3 is a risk factor for the development of diabetes: A population-based cohort study. Diabetes. 54, 570-575 (2005).
29. Nilsson, B. et al. C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors. Eur. J. Clin. Invest. 44, 587-596 (2014).
30. Warnberg, J. & Marcos, A. Low-grade inflammation and the metabolic syndrome in children and adolescents. Curr. Opin. Lipidol. 19, 11-15 (2008).
31. Song, K. et al. Serum immunoglobulin M concentration is positively related to metabolic syndrome in an adult population: Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIH) Cohort Study. PloS One 9, e88701 (2014).
32. Onat, A. et al. Cross-sectional study of complement C3 as a coronary risk factor among men and women. Clin. Sci. (Lond) 108, 129-135 (2005).
33. Phillips, C. M. et al. Dietary fat, abdominal obesity and smoking modulate the relationship between plasma complement component 3 concentrations and metabolic syndrome risk. Atherosclerosis. 220, 513-519 (2012).
34. Wamba, P. C. et al. Acylation stimulating protein but not complement C3 associates with metabolic syndrome components in Chinese children and adolescents. Eur. J. Endocrinol. 159, 781-790 (2008).
35. Cianflone, K., Lu, H., Smith, J., Yu, W. & Wang, H. Adiponectin, acylation stimulating protein and complement C3 are altered in obesity in very young children. Clin. Endocrinol (Oxf) 62, 567-572 (2005).
36. Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: A key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785-797 (2010).
37. Wlazlo, N. et al. Complement factor 3 is associated with insulin resistance and with incident type 2 diabetes over a 7-year follow-up period: The CODAM Study. Diabetes care. 37, 1900-1909 (2014).
38. Phieler, J. et al. The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance. J. Immunol. 191, 4367-4374 (2013).
39. Lim, J. et al. C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling. FASEB J. 27, 822-831 (2013).
40. Phieler, J., Garcia-Martin, R., Lambris, J. D. & Chavakis, T. The role of the complement system in metabolic organs and metabolic diseases. Semin. Immunol. 25, 47-53 (2013).
41. Grundy, S. M. et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit. Pathw. Cardiol. 4, 198-203 (2005).
42. Ahren, B., Havel, P. J., Pacini, G. & Cianflone, K. Acylation stimulating protein stimulates insulin secretion. Int. J. Obes. Relat. Metab. Disord. 27, 1037-1043 (2003).
43. Zhou, X. et al. Complement 3 activates the renal renin-Angiotensin system by induction of epithelial-To-mesenchymal transition of the nephrotubulus in mice. Am. J. Physiol. Renal. Physiol. 305, F957-967 (2013).
44. Zhang, Y. et al. Endogenous sex hormones and C-reactive protein in healthy Chinese men. Clin. Endocrinol. (Oxf) 78, 60-66 (2013).
45. Wu, C. et al. The association of smoking and erectile dysfunction: results from the Fangchenggang Area Male Health and Examination Survey (FAMHES). J. Androl. 33, 59-65 (2012).
46. Tan, A. et al. Low serum osteocalcin level is a potential marker for metabolic syndrome: results from a Chinese male population survey. Metabolism. 60, 1186-1192 (2011).